PepGen (PEPG) Insider Lisa Wyman Buys 34,000 Shares

Lisa Wyman Acquires Shares in PepGen

Lisa Wyman picked up 34,000 shares of PepGen Inc. (NASDAQGS:PEPG) on June 18, 2026. This transaction came to light through recent regulatory filings with the SEC. Wyman joined a group of key figures at the biotechnology firm who all bought identical blocks of stock on the exact same day.

Coordinated Insider Transactions at PepGen

On June 18, 2026, a wave of insider purchases hit the wire for the Boston-based firm. Alongside Wyman, insiders Howard Mayer, Joshua Resnick, Mitchell Finer, and Habib Dable each acquired 34,000 shares of PepGen. These matching acquisitions followed earlier disclosures from mid-June showing steady internal support for the clinical-stage biotech company as it moves its pipeline forward.

Stock Valuation and Trading Levels

Shares of PepGen traded at $1.83 on Tuesday. The stock has moved between a 52-week low of $1.31 and a high of $7.80 over the past year. Its current price sits below both its 50-day moving average of $2.67 and its 200-day moving average of $3.52. The company carries a market capitalization of roughly $196.7 million and a beta of 1.97, pointing to higher volatility than the broader market.

Analysts Set New Price Targets

Wall Street firms maintain an optimistic outlook on the company's prospects. On September 9, 2026, HC Wainwright & Co. reiterated its buy rating on the stock with a price target of $20.00. This follows earlier support in June from Craig-Hallum, which reaffirmed its buy rating with an $11.00 price target. Across the broader analyst community, the stock holds a consensus strong buy rating with a mean price target of $10.19. <div></div>

Advancing Treatments for Neuromuscular Diseases

PepGen Inc. operates as a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The firm works on treatments such as PGN-EDODM1 and FREEDOM2-DM1, which are both currently in Phase 2 clinical trials for myotonic dystrophy type 1. With a small team of 57 employees based in Boston, the company directs its resources toward tackling rare genetic conditions.

What to Watch Next for the Firm

Investors will look toward the company's next scheduled earnings report on November 11, 2026, for updates on clinical trial progress and financial standing. Insider transaction reports filed under SEC rules offer a backward-looking view of internal sentiment and do not guarantee future stock movements.